Unicycive Therapeutics Inc (NASDAQ: UNCY) is 68.26% higher on its value in year-to-date trading and has touched a low of $0.47 and a high of $2.29 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The UNCY stock was last observed hovering at around $1.37 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $1.46, the stock is 1.49% and 11.06% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.06 million and changing 6.57% at the moment leaves the stock 50.74% off its SMA200. UNCY registered -34.53% loss for a year compared to 6-month gain of 64.04%. The firm has a 50-day simple moving average (SMA 50) of $62.01 and a 200-day simple moving average (SMA200) of -$1.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -0.68% loss in the last 1 month and extending the period to 3 months gives it a 71.76%, and is 0.00% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.57% over the week and 8.66% over the month.
Unicycive Therapeutics Inc (UNCY) has around 14 employees, a market worth around $50.75M and $0.68M in sales. Profit margin for the company is -4625.04%. Distance from 52-week low is 210.64% and -36.16% from its 52-week high.
Unicycive Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.19.The EPS is expected to grow by 54.43% this year, but quarterly earnings will post 270.40% year-over-year.
19 institutions hold shares in Unicycive Therapeutics Inc (UNCY), with institutional investors hold 60.27% of the company’s shares. The shares outstanding are 34.76M, and float is at 24.99M with Short Float at 0.23%. Institutions hold 49.18% of the Float.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 0.65 million shares valued at $0.83 million. The investor’s holdings represent 1.86% of the UNCY Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 0.12 million shares valued at $0.15 million to account for 0.33% of the shares outstanding. The other top investors are Goldman Sachs Group Inc which holds 95931.0 shares representing 0.28% and valued at over $0.12 million, while Geode Capital Management, LLC holds 0.19% of the shares totaling 66752.0 with a market value of $85442.0.
